Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC +6.52%64 EV-to-EBIT is 6.15 as of Jul. 16, 2026, which is 377% above its 10-year median of 1.29. GuruFocus rates UPC with a GF Score™ of 64/100 and a GF Value™ of $5.18 (Fairly Valued). The stock has 7 warning signs investors should review. Among 688 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 86.34% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Universe Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2025 was $-21.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $-3.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals EV-to-EBIT Related Terms
Universe Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's EV-to-EBIT falls into.
Universe Pharmaceuticals's current Enterprise Value is $-21.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $-3.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a EV-to-EBIT of 6.15 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Universe Pharmaceuticals and its competitors. This is 377% above median its historical median of 1.29. According to the industry distribution chart, Universe Pharmaceuticals ranks #94 out of 688 companies in the Drug Manufacturers industry, placing it in the top 13.7%.
Is Universe Pharmaceuticals' EV-to-EBIT too high?
Universe Pharmaceuticals' current EV-to-EBIT of 6.15 is 377% above median its 10-year median of 1.29. The Drug Manufacturers industry median EV-to-EBIT is 15.71. Universe Pharmaceuticals' value of 6.15 is 60.8% below this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #94 out of 688 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' EV-to-EBIT compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #94 out of 688 companies for EV-to-EBIT. This places Universe Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.71. Universe Pharmaceuticals' value of 6.15 is 60.8% below this benchmark. While the company's 10-year median is 1.29 vs. the industry median of 15.71, Universe Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current EV-to-EBIT of 6.15 is 60.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current EV-to-EBIT is 6.15, which is 377% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Fairly Valued. The stock's GF Value™ is $5.18, compared to a current price of $4.90 — trading 5.4% below its estimated fair value. The current EV-to-EBIT is 6.15, which is 377% above median its 10-year median of 1.29 and 60.8% below the Drug Manufacturers industry median of 15.71. Universe Pharmaceuticals' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current EV-to-EBIT is 6.15 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.90 is trading 5.4% below its estimated GF Value™ of $5.18.
GuruFocus considers Universe Pharmaceuticals to be Fairly Valued.
Key valuation signals for UPC:
EV-to-EBIT: 6.15 (377% above median its 10-year median of 1.29)
GF Value™: $5.18 vs. price of $4.90 (5.4% below fair value)
Industry Position: 60.8% below the Drug Manufacturers median (#94 of 688)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
64GF Score
Get the complete analysis for UPC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
